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Objective. To compare the direct mental health care costs between individuals with Seasonal Affective Disorder randomized to
either fluoxetine or light therapy. Methods. Data from the CANSAD study was used. CANSAD was an 8-week multicentre double-
blind study that randomized participants to receive either light therapy plus placebo capsules or placebo light therapy plus fluo-
xetine. Participants were aged 18–65 who met criteria for major depressive episodes with a seasonal (winter) pattern. Mental
health care service use was collected for each subject for 4 weeks prior to the start of treatment and for 4 weeks prior to the end of
treatment. All direct mental health care services costs were analysed, including inpatient and outpatient services, investigations, and
medications. Results. The difference in mental health costs was significantly higher after treatment for the light therapy group
compared to the medication group—a difference of $111.25 (z = −3.77, P = 0.000). However, when the amortized cost of the
light box was taken into the account, the groups were switched with the fluoxetine group incurring greater direct care costs—
a difference of $75.41 (z = −2.635, P = 0.008). Conclusion. The results suggest that individuals treated with medication had
significantly less mental health care cost after-treatment compared to those treated with light therapy.
1. Introduction
Seasonal Affective Disorder (SAD) is a subtype of major dep-
ression that recurs on an annual basis. In the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), SAD is classified as a seasonal pattern specifier
for major depressive disorder or bipolar disorder [1]. There
is a significant burden of illness associated with SAD, and
research demonstrates that individuals with SAD utilize
significantly more health care services compared to age-
matched controls without SAD [2–4].
There are two evidence-based treatments for SAD—anti-
depressants and light therapy. The efficacy of both of these
treatments has been demonstrated in randomized controlled
trials [5–7]. Studies have shown that individuals treated
for SAD not only have improved symptoms but also have
improved quality of life [8]. Light therapy and antidepres-
sants are now recommended as first-line treatments for
SAD in several clinical guidelines including the Canadian
Network for Mood and Anxiety Treatments (CANMAT) [9],
the American Psychiatric Association [10], the British Asso-
ciation of Psychopharmacology [11], and the World Federa-
tion of Societies of Biological Psychiatry [12].
The largest Canadian treatment study to date, CANSAD,
compared antidepressants and light therapy in a randomized
controlled trial and found that symptom reduction, response
and remission rates, and improvement in quality of life were
similar in patients with SAD treated with fluoxetine or light
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therapy [13]. However, there is little known about the direct
mental health care costs for individuals treated for SAD and
the cost differences between these two treatments.
2. Aims of the Study
The objective of this study was to compare the direct mental
health care costs between individuals with SAD randomized
to either fluoxetine or light therapy using data from the
CANSAD trial.
3. Methods
3.1. Main Study and Findings. CANSAD was an 8-week
multi-centre double-blind study that randomized partici-
pants to receive either active light therapy plus placebo cap-
sules or placebo light therapy plus fluoxetine [13]. Briefly, the
participants were aged 18–65 who met DSM-IV criteria for
major depressive episodes with a seasonal (winter) pattern
and were at least moderately depressed as determined by
a baseline score of 23 or higher on the 24-Item Hamilton
Depression Rating Scale (HAM-D). A total of 95 participants
were included in this study sample (light therapy n = 48,
fluoxetine n = 47). The active light therapy group had daily
exposure to a white, 10,000 lux fluorescent light box for
30 minutes in the early morning. The active medication
group received fluoxetine 20mg once daily. There were 6
study visits: screening, baseline, weeks 1, 2, 4, and 8. Light
therapy and fluoxetine both reduced SAD symptoms with no
significant differences as measured by the HAM-D but those
treated with fluoxetine endorsed more adverse effects such as
palpitations. The two treatments had similar response and
remission rates. The results also remained the same when
the authors only included those individuals with more severe
depression in the analysis. A full description of the study
design and the main findings can be found elsewhere [8, 13].
3.2. Economic Evaluation. Mental health care service and
drug use for CANSAD was collected for each subject for 4
weeks prior to the start of treatment and for 4 weeks prior
to the end of treatment. Data were collected using the Health
Utilization Study Instrument which has been used in previ-
ous research in Canada [14]. All direct mental health care
services costs were analysed, including inpatient services,
outpatient services, clinical and laboratory investigations,
and medications. Direct care costs were divided into two
categories: (1) mental health care costs and (2) prescription
and over the counter drug costs. Mental health care costs
were derived from the Approach to the Measurement of
Costs Health Utilization Study [15]. Prescription drug costs
were provided by the Drug Information Service, a regional
independent drug information agency funded by the gov-
ernment based on drug costs for a large academic hospital
in Southern Ontario, Canada. Prescription drug costs in
Ontario are considered an average of costs among other
jurisdictions in Canada. Over-the-counter drug costs were
Table 1: Health care services and classes of drugs used by study
participants.
Type of health care services Classes of drugs
Emergency services Analgesics
Inpatient services Anxiolytics
Laboratory services Antibiotics/antimicrobials
Medical imaging Antidepressants
Nursing Antihypertensives
Occupational therapy Antilipids
Physician services Birth control
Physiotherapy Decongestants
Psychologist services Hormone replacement therapy
Social work Nutritional supplements/vitamins
Sedatives
Steroids
calculated using the average price of the drugs if they were
purchased at (1) a discount pharmacy or (2) a nondiscount
pharmacy. If an individual reported a generic name for a
drug, the costs were determined on the generic version (see
Table 1 for full list of services and drugs). All costs were calcu-
lated in Canadian dollars. Since both groups had the same
number of visits throughout the course of the study, the costs
of these visits were not included in our analyses.
The costs of the two study treatments were also included
in the analysis. The cost of the fluoxetine was estimated at
$40 for the course of the 8-week trial. The estimated upfront
cost of the light box was $200 (total purchase price per unit).
For comparison to the short-term costs of medication, we
derived the cost of light therapy not based on the one-time
up-front cost of the light box ($200) but rather the 2-month
cost of a light box amortized over the lifetime use of the
device. The amortized monthly cost of the device was calcu-
lated based on the 5 years of usual clinical use (and on 5
months of seasonal use per 12-month period) before the
device or replacement bulbs are required for the device. This
cost was estimated at $13.33 for the 8 weeks of this acute
treatment trial.
3.3. Analyses. The average direct mental health care cost
differences before treatment (4 weeks prior to initiation of
treatment) and after treatment (4 weeks prior to the end of
treatment) for SAD for the two treatment groups were cal-
culated. Since the data are not normally distributed, non-
parametric tests (Wilcoxon rank-sum test) were conducted
to examine for differences in average pre- and posttreatment
costs between the two groups. To give a broader perspective
on costs, we also examined the average cost differences bet-
ween the two groups based on all direct health care costs
(mental health and nonmental or general health related
costs).
We also conducted sensitivity analyses, to examine dif-
ferences in costs using the full up-front purchase cost of the
light box ($200) versus the amortized cost of $13.33 for the
acute treatment phase.
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Table 2: Total health care costs and cost differences based on full purchase cost of light box between fluoxetine and light therapy arms.
Type of cost Mental-health-related costs Mental- and non-mental-health-related costs
Treatment group Medication Light Medication Light
Direct health care costs Before
1 71.72 (158.68) 86.37 (203.68) 109.50 (186.77) 126.73 (238.13)
After2 122.17 (117.75) 312.78 (186.09) 213.68 (263.29) 355.41 (234.47)
Drug costs Before
3 10.82 (21.74) 22.86 (56.93) 10.82 (21.74) 22.86 (56.93)
After4 62.80 (70.60) 14.63 (55.46) 62.80 (70.60) 14.63 (55.46)
Total costs
Before5 82.35 (156.84) 109.23 (217.14) 120.18 (183.33) 149.60 (251.50)
After6 184.95 (142.41) 327.41 (194.72) 276.48 (279.43) 369.77 (239.40)
Mean of individual differences
between before and after7
96.40 (206.29)∗ 207.65 (259.42)∗ 168.72 (302.09)∗∗ 197.84 (318.58)∗∗
∗
P < 0.0001.
∗∗Not statistically significant.
Notes: medication: fluoxetine 20mg once daily, light therapy: light box 30 minutes per day, SD: standard deviation.
∗Statistically significant differences were found between the fluoxetine group and light therapy group.
†Participants were randomized to either fluoxetine 20mg once daily or light box 30 minutes each day.
1Total health care costs for the 4 weeks prior to enrollment in study.
2Total health care costs for the 4 weeks prior to the end of the study.
3Total drug costs for the 4 weeks prior to enrollment in study.
4Total drug costs for the 4 weeks prior to the end of the study.
5Total health care and drugs costs for the 4 weeks prior to enrollment in study.
6Total health care and drug costs for the 4 weeks prior to the end of the study.
7The difference in total health care and drug costs for the 4 weeks prior to the enrollment of the study and for the 4 weeks prior to the end of the study.
4. Results and Discussion
4.1. Results. The cost difference for mental health costs only
was significantly higher after treatment for the light therapy
group compared to the medication group—a difference of
$111.25 (z = −3.77, P = 0.000) (see Table 2). Similarly, the
cost difference in general health care costs (mental-health
related and nonmental health or general health related costs)
between the two treatment groups was also significantly
higher in the light therapy group, although the difference was
smaller at $29.12 and not statistically significant (z = −1.85,
P = 0.64).
We also conducted sensitivity analyses using the amor-
tized cost of the light box. In contrast to the primary ana-
lyses, overall, the mental health care cost difference was sig-
nificantly higher after treatment for the medication group
compared to the light therapy group—a difference of $75.41
(z = −2.635, P = 0.008). The cost difference in general
health care costs (mental-health related and non mental
health or general health related costs) also remained higher
for the medication group (z = −2.509, P = 0.012).
4.2. Discussion. This study examined the differences in direct
mental health care costs of individuals with SAD treated
within a randomized controlled trial comparing fluoxetine
and light therapy treatment. Overall, the direct health care
costs for patients with SAD were generally low with the aver-
age cost less then $200 over 4 weeks. This cost is less than half
of the estimated direct care costs of individuals with stable
major depression treated with antidepressants [16]. How-
ever, patients with SAD are often treated with combination
treatment of both light therapy and antidepressants. The use
of combination therapy could have a significant impact on
the total direct care costs incurred by individuals with SAD.
The results suggest that in the acute 8-week treatment
phase, participants treated with fluoxetine had significantly
less mental health services cost compared to those treated
with light therapy. However, the opposite results were found
if the amortized cost of the light box was taken into account
rather than the whole up-front cost of the purchase of a light
box. Furthermore, although the light box is more expensive
when initially purchased, it can be used during the entire
episode with no extra cost and then again for the treatment
of subsequent episodes over several years whereas the cost
of medications is ongoing. This is particularly important in
individuals with SAD because it is a recurrent illness and the
depressive episodes tend to recur annually. For example, par-
ticipants in the CANSAD study had experienced an average
of 11 lifetime winter depressive episodes prior to study entry
[13]. This is almost double the average number of episodes of
participants with unipolar depression (average of 6 previous
episodes) who were enrolled in the STAR∗D treatment trial
[17].
In addition, experts recommend that individuals with
SAD initiate treatment several months prior to the start
of winter each year in order to prevent onset of SAD and
continue treatment until the end of winter, totaling an
average of 5months of treatment per calendar year [18]. Each
$200 light box unit is expected to last for 5 years with low
ongoingmaintenance costs of approximately $25 over 5 years
while the cost of fluoxetine is $24 per month. Therefore, the
total cost of treating annual episodes of SAD for 5 years at 5
months of treatment per year would be $600 for fluoxetine
and $200 for light therapy. Based on these estimates, light
therapy is more expensive than fluoxetine in the first year
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of treatment but becomes cost saving after the second year
of treatment (and for every subsequent year) compared to
medications. In addition, the cost savings for light therapy
would be even greater if (1) nongeneric medications, which
have higher costs than the generic fluoxetine used in this
study, were prescribed for treatment, or (2) the dose of fluo-
xetine was greater than 20mg daily.
Finally, in the sensitivity analyses where the amortized
cost of the light box was used, those treated with fluoxetine
also incurred greater costs when mental health and non-
mental health care costs were both considered. One possible
explanation for this finding is that individuals treated with
fluoxetine had higher rates of some adverse effects such as
gastrointestinal upset (e.g., nausea, diarrhea) and palpita-
tions and therefore may utilize more health care services due
to increased physical complaints compared to those treated
with light therapy.
A limitation to this study is that CANSAD was an acute
treatment study and therefore, interpretation of the data is
limited to the costs associated with short-term health services
utilization of the CANSAD participants. In addition, costs
associated with fluoxetine may or may not be similar to other
antidepressants, particularly those where generics are still
not available (e.g., duloxetine) and costs associated with the
particular light box used in this study may or may not be
generalizable to all light therapy units available on the mar-
ket. However, the costs used in this study are representative
of the average costs of generic antidepressant medications
and light therapy units. In addition, patients were treated as
part of a clinical trial, and health care costs in a “real world”
situation may be different in unpredictable ways. However,
this is the first study to report the direct care costs associated
with treatment of SAD and therefore provides important
information regarding the costs of managing this common
and recurrent disorder. Patients often prefer nonmedication
approaches in the treatment of depression [19], and this
study suggests that the health care costs of light therapy may
also be favourable compared to medication treatment, parti-
cularly in the long term. Given that there were no significant
differences in response or remission rates found between the
two treatments in the original study, health care providers
such as government or private health insurance companies
may be justified in simply choosing the most cost-saving
treatment for individuals with SAD.
5. Conclusions
This is the first study to compare the direct mental health care
costs between individuals with SAD randomized to either
medication or light therapy. The findings suggest that indi-
viduals treated with fluoxetine had significantly less mental
health care cost after treatment compared to those treated
with light therapy. However, if the cost of the light box
is amortized, we find the opposite results—favouring light
therapy. These results may be of value to patients and clini-
cians in considering the cost/benefit of SAD treatments and
may assist health services payors with respect to support for
these treatments.
Significant Outcomes
(1) Overall, direct care costs of individuals with Seasonal
Affective Disorder were less expensive then the esti-
mated care costs for those with unipolar depression.
(2) With recurrent episodes of Seasonal Affective Disor-
der, light therapy is a cost-saving treatment option.
(3) Using the amortized cost (over 5 years) instead of the
upfront purchase cost of the light box in the analyses
makes light therapy the cost-saving treatment option
over fluoxetine for acute treatment.
(4) If the up-front purchase cost of the light box (instead
of the amortized cost over 5 years) is used in the
analyses, fluoxetine is the cost-saving treatment over
light therapy for acute treatment of SAD.
Limitations
(1) Data is limited to acute treatment.
(2) Costing information is limited to direct care costs and
excludes other societal costs.
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